The UK Advanced Therapy Treatment Centre (ATTC) network has announced it has been awarded a total of £9.5 million enabling its work to continue until at least March 2022.
Of the funding, £6.5 million comes from the Department for Business, Energy and Industrial Strategy (BEIS) and, £3 million specifically from its Industrial Strategy Challenge Fund (ISCF).
Matthew Durdy, CEO, CGT Catapult commented:
“The ATTC network is a fantastic example of effective Government intervention and the international community recognises this as part of the UK’s leadership in the field. Bringing together companies, the NHS and regulatory bodies to make the use of cell and gene therapies easier, more cost effective, and more widespread both boosts the industry and brings these life changing medicines to patients who need them. The fact that 12% of global clinical trials in cell and gene therapy take place in the UK and half of those involve ATTCs is a testament to the success of this highly respected programme.”
The ATTC network carries out activities including finding best practices for implementing cell and gene therapies in the NHS – crucial work for therapies perceived as high-cost and technically demanding.
Read the ATTC network’s announcement for more information.